Skip to main content
Premium Trial:

Request an Annual Quote

Burnham Institute Becomes NCI Chemical Biology Center

NEW YORK (GenomeWeb news) – The Burnham Institute for Medical Research will conduct research on oncology drug targets and cancer biology as part of efforts to develop personalized medical approaches to cancer for the National Cancer Institute, Burnham said on Monday.

NCI has named Burnham a Comprehensive Center in its Chemical Biology Consortium, which is a network of molecular oncologists, chemical biologists, and chemical screening centers, and it will conduct the work at the Burnham campuses in La Jolla, Calif., and in Orlando, Fla.

"The Chemical Biology Consortium gives Burnham an additional platform to use our advanced technologies, some of which are virtually unprecedented in the not-for-profit research world," Burnham CEO and President John Reed said in a statement.

Last year, Burnham won a $98 million grant to serve as a comprehensive national screening center for the National Institute of Health's Molecular Libraries Probe Production Centers Network, and it also recently received $10 million from the philanthropist Conrad Prebys for its Center for Chemical Genomics.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.